|
See related Lantus information |
|
|
|
Manufacturer |
sanofi-aventis |
|
Distributor |
Hong Kong: LF Asia/Macau: Four Star |
|
Contents |
Insulin glargine |
|
Indications |
Treatment of adults, adolescents & childn ≥6 yr w/ DM where treatment w/ insulin is required.
Click to view Lantus detailed prescribing infomation |
|
Dosage |
Inject SC once daily.
Click to view Lantus detailed prescribing infomation |
|
Overdosage |
View Lantus overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
[Click for Lantus detailed prescribing infomation] |
|
Special Precautions |
Renal & severe hepatic impairment. Hypoglycaemia, significant narrowing of coronary or cerebral arteries, proliferative retinopathy. Concomitant illness. May impair ability to drive or operate machinery.
Click to view Lantus detailed prescribing infomation |
|
Adverse Drug Reactions |
Hypoglycaemia, temporary visual impairment, lipodystrophy, inj site reactions including pain, erythema, itch, hives, swelling or inflammation. Rarely, severe allergic reactions.
View ADR Monitoring Form |
|
Drug Interactions |
Effects enhanced by oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, sulfonamide antibiotics. Effects reduced by corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics, thyroid hormones, PIs & atypical antipsychotic medications. β-blockers, clonidine, lithium or alcohol may either potentiate or weaken the effects of insulin. Pentamidine may cause hypoglycaemia, sometimes followed by hyperglycaemia. β-blockers may mask hypoglycaemia.
View more drug interactions with Lantus |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Lantus storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Lantus description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Lantus mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
